Mimedx (MDXG) Convertible Debt (2011 - 2012)
Mimedx (MDXG) reported Convertible Debt of $4.0 million for Q4 2012, up 46.19% on a YoY basis from $2.7 million in Q1 2012, and up 14.85% sequentially from $3.5 million in Q3 2012.
Mimedx (MDXG) Convertible Debt (2011 - 2012) Analysis & Trends
Mimedx (MDXG) has 2 years of Convertible Debt data on file, last reported at $4.0 million in Q4 2012.
- For the quarter ending Q4 2012, Convertible Debt rose 46.19% year-over-year to $4.0 million; the trailing twelve-month figure through Dec 2012 stood at $4.0 million (up 46.19% YoY), and the FY2012 full-year result was $4.0 million, up 46.19% from the prior year.
- Convertible Debt rose to $4.0 million in Q4 2012, from $3.5 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $4.0 million in Q4 2012 to a low of $959209.0 in Q2 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Mimedx | 647.22 Mn | 487.45 Mn | 41.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | 4.01 Mn |
| Sep 30, 2012 | 3.49 Mn |
| Jun 30, 2012 | 3.24 Mn |
| Mar 31, 2012 | 3.02 Mn |
| Dec 31, 2011 | 2.74 Mn |
| Jun 30, 2011 | 959,209.00 |